We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Rapid Mass Spectrometry Technique Identifies Brain Tumors in Situ

By HospiMedica International staff writers
Posted on 20 Feb 2013
A new diagnostic tool could provide near-real time intraoperative molecular diagnosis and margin assessment of brain tumors, according to a new study. More...


Researchers at Purdue University (Purdue, West Lafayette, IN, USA) and Brigham and Women's Hospital (Boston, MA, USA) developed the new tool, which sprays a microscopic stream of charged solvent onto tissue surfaces to gather information on molecular makeup, producing a color-coded image that reveals the nature and concentration of tumor cells. The tool relies on an ambient mass spectrometry analysis technique called desorption electrospray ionization (DESI), which evaluates the distribution and amounts of lipids within the brain tissue.

While conventional mass spectrometry requires chemical separations, manipulations of samples, and containment in a vacuum chamber for ionization and analysis, the DESI technique eliminates these requirements by performing the ionization step directly on surfaces outside of the mass spectrometers. Lipid patterns that correspond to the different types and grades of cancer and concentrations of tumor cells can then be identified using a software program that characterizes the brain tumors, detect boundaries between healthy and cancerous tissue, and displays the results in a color-coded map. The study was published on January 29, 2013, in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).

“We hope to eventually be able to perform this analysis during surgery to help guide brain surgeons so that the borders of tumors can be identified and the cancer status of a site can be established before any tissue is removed,” said lead author Professor of Chemistry R. Graham Cooks, PhD, of Purdue. “We aren't there yet, but this was a critical step in the process. It shows we've found easily identifiable molecular patterns that can be used to diagnose the type and concentration of cancer cells.”

“The new tool is able - in a matter of seconds - to identify and classify glioma and meningioma tumors and recognize the tumor grade,” said study coauthor Sandro Santagata, MD, a pathologist at Brigham and Women's Hospital. “It is able to establish the same type of assessment the pathology offers, but at a pace that is compatible with surgery.”
Pathological examination of specimens taken from the brain during surgery provides the most specific information about the tissue and diagnosis of the cancer. However, this examination of frozen sections takes about half an hour, which is too long for it to be useful in examining multiple samples and guiding surgery.

Related Links:

Purdue University
Brigham and Women's Hospital




Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.